The calcium channel blocker nitrendipine attenuates renal and glomerular hypertrophy in diabetic rats

Experimental Nephrology

Volumn 7, Issue 3, 1999, Pages 242-250

  Nielsen, Birgitte ^a,b   Grønbæk, Henning ^a   Østerby, Ruth ^a   Ørskov, Hans ^a   Flyvbjerg, Allan ^a  

^a University Institute of Pathology Arhus   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Calcium channel blocker; Diabetes; Kidney morphology; Nitrendipine; Rat; Renal hypertrophy; Streptozotocin; Urinary albumin excretion

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; FRUCTOSAMINE; GLUCOSE; NITRENDIPINE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; FEMALE; FOOD INTAKE; KIDNEY HYPERTROPHY; KIDNEY MASS; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033036316     PISSN: 10187782     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020608     Document Type: Article

References (45)

1. Mogensen CE, Andersen MJ: Increased kidney size and glomerular filtration rate in early juvenile diabetes. Diabetes 1973;22:706-712.
2. Seyer Hansen K: Renal hypertrophy in experimental diabetes mellitus. Kidney Int 1983;23: 643-646.
3. Hostetter TH, Troy JL, Brenner BM: Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981;19:410-415.
4. Mogensen CE, Christensen CK: Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984;311:89-93.
5. Mogensen CE, Christensen CK, Christiansen JS, Boye N, Pedersen MM, Schmitz A: Early hyperfiltration and late renal damage in insulin-dependent diabetes. Pediatr Adol Endocrinol 1988;17:197-205.
6. Mogensen CE: Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy. Scand J Clin Lab Invest 1986;46: 201-206.
7. O'Brien RC, Cooper ME, Jerums G, Doyle AE: The effects of perindopril and triple therapy in a normotensive model of diabetic nephrophaty. Diabetes 1993;42:604-609.
8. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-1930.
9. Anderson S, Rennke HG, Garcia DL, Brenner BM: Short- and long-term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989;36:526-536.
10. Mogensen CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982;285:685-688.
11. Melbourne Diabetic Nephropathy Study Group: Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 1991;302:210-216.
12. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
13. Bretzel RG, Bollen CC, Maeser E, Federlin KF: Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. Am J Kidney Dis 1993;21:53-64.
14. Jungmann E, Malanyn M, Mortasawi N, Unterstöger, Haak T, Palitzsch K-D, Scherberich J, Schumm-Draeger P-M, Usadel KH: Effect of 1-year treatment with nitrendipine versus enalapril on urinary albumin and alpha 1-microglobulin excretion in micralbuminuric patients with type 1 diabetes mellitus: A randomized, single-blind comparative study. Arzneimittelforschung 1994;44:313-317.
15. Ruggenenti P, Mosconi L, Bianchi L, Cortesi L, Campana M, Pagani G, Mecca G, Emuzzi G: Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. Am J Kidney Dis 1994;24:753-761.
16. Mosconi L, Ruggenenti P, Perna A, Mecca G, Remuzzi G: Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int 1996;49:S91-S93.
17. Baba T, Murabayashi S, Takebe K: Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: A randomised controlled trial. Diabetologia 1989;32:40-44.
18. Maunsbach AB: The influence of different fixatives and fixation methods on the ultrastructure of rat kidney proximal tubule cells. II. Effects of varying osmolality, ionic strength, buffer system and fixative concentration of glutaraldehyde solutions. J Ultrastruct Res 1966; 15:283-309.
19. Boye N, Ingerslev J: Rapid and inexpensive microdetermination of serum fructosamine results in diabetics, uraemics, diabetics with uraemia and healthy subjects. Scand J Clin Lab Invest 1988;48:779-783.
20. Rasch R: Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment: Albumin excretion. Diabetologia 1980;18:413-416.
21. Pfeffer JM, Pfeffer MA, Frohlich ED: Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. J Lab Clin Med 1971;78:957-962.
22. Gundersen HJ: The new stereological tools. APMIS 1988;96:379-394.
23. Gundersen HJ: The new stereological tools. APMIS 1988;96:857-881.
24. Flyvbjerg A, Ørskov H: Kidney tissue insulin-like growth factor I and initial renal growth in diabetic rats: Relation to severity of diabetes. Acta Endocrinol (Copenh)1990;122:374-378.
25. Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH: Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997; 46:481-487.
26. Bakris GL, Barnhill BW, Sadler R: Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int 1992;41:912-919.
27. Demarie BK, Bakris GL: Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 113:987-988.
28. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R: Effect of calcium channel or betablockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997;29:744-750.
29. Bakris GL: Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990;112:707-708.
30. Holdaas H, Hartmann A, Lien MG, Nilsen L, Jervell J, Fauchald P, Endresen L, Djøseland O, Berg KJ: Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin-dependent diabetics with nephropathy. J Intern Med 1991;229: 163-170.
31. Mimran A, Insua A, Ribstein J, Monnier L, Bringer J, Mirouze J: Contrasting effects of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. J Hypertension 1988;6:919-923.
32. Corcoran JS, Perkins JE, Hoffbrand BI; Yudkin JS: Treating hypertension in non-insulin-dependent diabetes: A comparison of atenolol, nifedipine, and captopril combined with bendrofluazide. Diabetic Med 1987;4:164-168.
33. Romero R, Salinas I, Lucas A, Teixido J, Audi L, Sanmarti A. Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. Diabetes Res Clin Pract 1992;17:191-198.
34. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Spalluto A, Vanasia A, Marco Villa G, Nosadini R: Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998;21:104-110.
35. Ferder L, Daccordi H, Martello M, Panzalis M, Inserra F: Angiotensin-converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992;19:237-242.
36. Østerby R, Gundersen HJ: Glomerular size and structure in diabetes mellitus. I. Early abnormalities. Diabetologia 1975;11:225-229.
37. Flyvbjerg A, Marshall SM, Frystyk J, Hansen KW, Harris AG, Ørskov H: Octreotide administration in diabetic rats: Effects on renal hypertrophy and urinary albumin excretion. Kidney Int 1992;41:805-812.
38. Hajinazarian M, Cosio FG, Nahman NS, Mahan JD: Angiotensin-converting enzyme inhibition partially prevents diabetic organomegaly. Am J Kidney Dis 1994;23:105-117.
39. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen L, Jerums G, Cooper ME: Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes. Diabetes 1998;47:414-422.
40. Morelli E, Loon N, Meyer TW, Peters W, Myers BD: Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990;39:76-82.
41. Reddi AS, Ramamurthi R, Miller M, Dhuper S, Lasker N: Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol 1991;45:119-131.
42. New JP, Canavan JP, Flyvbjerg A, Hamon G, Bilous RW, Marshall SM: Renal enlargement and insulin-like growth factor-1 accumulation in the Wistar rat model of experimental diabetes is not prevented by angiotensin converting enzyme inhibition. Diabetologia 1996;39: 166-171.
43. Hasslacher C, Stech W, Wahl P, Ritz E: Blood pressure and metabolic control as risk factors for nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 1985;28:6-11.
44. Gansevoort RT, Apperloo AJ, Heeg JE, de Jong PE, de Zeeuw D: The antiproteinuric effect of antihypertensive agents in diabetic nephropathy. Arch Intern Med 1992;152: 2137-2139.
45. Loutzenhiser R, Epstein M: Effects of calcium antagonists on renal hemodynamics. Am J Physiol 1985;249:F619-F629.